Arrowhead Pharmaceuticals, Inc. (ARWR)
67.60
-1.23
(-1.79%)
USD |
NASDAQ |
Dec 10, 11:46
Arrowhead Pharmaceuticals EPS Diluted (Quarterly): -0.175 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | -1.795 |
| Ionis Pharmaceuticals, Inc. | -0.805 |
| Alnylam Pharmaceuticals, Inc. | 1.840 |
| Amgen, Inc. | 5.934 |
| Novartis AG | 2.020 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 16.12M |
| Revenue (Quarterly) | 256.47M |
| Total Expenses (Quarterly) | 280.22M |
| Enterprise Value | 9.199B |
| Gross Profit Margin (Quarterly) | 97.51% |
| Profit Margin (Quarterly) | 6.29% |
| Earnings Yield | -0.10% |
| Operating Earnings Yield | 1.09% |
| Normalized Earnings Yield | -0.0994 |